DEEPVESSEL FFR is a software medical device that uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiography (CCTA). The software processes coronary CTA images semi-automatically, generates a three-dimensional model of the coronary artery tree, and estimates CT FFR values. DEEPVESSEL FFR is FDA-Cleared, CE-Marked, NMPA-Cleared, HSA-Certified.

Keya Medical is an international medical technology company developing deep learning-based medical devices for disease diagnosis and treatment. The company is committed to creating solutions that deliver clinical value at all stages in the patient care process, covering specialties including cardiology, neurology, pulmonology, pathology, and surgery. Keya Medical has four centers in Beijing, Shanghai, Shenzhen, and Seattle. 

The deep-learning-based CT FFR analysis DEEPVESSEL FFR is the company's flagship product. The AI CT FFR is FDA-cleared, CE-marked, and NMPA-approved. DEEPVESSEL FFR is a software medical device that uses deep learning technology to perform a non-invasive physiological functional assessment of the coronary arteries using coronary computed tomography angiography (CCTA). 

Web-based clinical intelligence platform, primarily utilized in critical care units to guide clinical decisions. The platform has full interoperability with the Electronic Health Record, and combines all relevant data within the complex critical care environment into one visualization to provide a full picture of a patient and their longitudinal trends. FDA-cleared algorithms continually assess the incoming patient information and provide early warning signs of clinical deterioration to aid care teams with determining interventions and treatment. Automated clinical workflows, customized to each individual ICU, provide care efficiency and positively impact clinical outcomes. 

Published clinical outcomes showing:

• Up to 36% reduction in ICU length of stay
• 41% reduction in ICU readmissions
• 22% reduction in time on ventilation
• 18% reduction in time on vasoactive medication

Commercial stage company with market leading AI clinical decision support platform for bedside and remote monitoring of high acuity patients. Published outcomes and strong ROI; utilized in 40+ hospitals & health systems.

Deep Learning

Accurate

Fast

Comprehensive

Flexible Payment Model

Accessible

Deep Learning

Accurate

Fast

Comprehensive

Flexible Payment Model

Accessible

Etiometry provides functionality to seamlessly extend the EHR to be effective for care in high-acuity patient settings (e.g. ICU), including automating clinical workflows, and providing in-depth, longitudinal trends.

Etiometry is the only CDS platform with 4 FDA-cleared risk algorithms and the platform's data collection capabilities have led to a vastly larger number of supporting clinical studies (>150).